Erratum: Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder (Current Psychiatry Reports (2010) 12 (366-373) DOI: 10.1007/s11920-010-0136-4);Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder

Current Psychiatry Reports

Volumn 12, Issue 5, 2010, Pages 366-373

  Cinnamon Bidwell, L ^a   Dew, Rachel E ^a   Kollins, Scott H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADHD; Clonidine; Guanfacine; Noradrenaline; Prefrontal

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ATOMOXETINE; CLONICEL; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE BETA MONOOXYGENASE; GUANFACINE; INTUNIV; PLACEBO; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADRENERGIC SYSTEM; ATTENTION; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; LOCUS CERULEUS; MENTAL PERFORMANCE; NEUROMODULATION; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PAIN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PULSE RATE; QT INTERVAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TIC; WORKING MEMORY;

EID: 77958179018     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0171-1     Document Type: Erratum

References (79)

1. TE Froehlich BP Lanphear JN Epstein, et al. 2007 Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children Arch Pediatr Adolesc Med 161 857 864 10.1001/archpedi.161.9.857 17768285 (Pubitemid 47360887)
2. RC Kessler L Adler R Barkley, et al. 2006 The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication Am J Psychiatry 163 716 723 10.1176/appi.ajp.163.4.716 16585449 (Pubitemid 44464584)
3. RC Kessler L Adler M Ames, et al. 2005 The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers J Occup Environ Med 47 565 572 10.1097/01.jom.0000166863.33541.39 15951716 (Pubitemid 40847440)
4. HG Birnbaum RC Kessler SW Lowe, et al. 2005 Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000 Curr Med Res Opin 21 195 206 10.1185/030079904X20303 15801990 (Pubitemid 40469896)
5. TW Frazier EA Youngstrom JJ Glutting MW Watkins 2007 ADHD and achievement: meta-analysis of the child, adolescent, and adult literatures and a concomitant study with college students J Learn Disabil 40 49 65 10.1177/00222194070400010401 17274547
6. J Biederman RD Melmed A Patel, et al. 2008 A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder Pediatrics 121 e73 e84 10.1542/peds.2006-3695 18166547
7. TE Wilens M Gignac A Swezey, et al. 2006 Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications J Am Acad Child Adolesc Psychiatry 45 408 414 10.1097/01.chi.0000199027.68828.b3 16601645 (Pubitemid 43675545)
8. L Scahill 2009 Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness CNS Drugs 23 Suppl 1 43 49 1:CAS:528: DC%2BD1MXhtVGit7%2FE 10.2165/00023210-200923000-00006 19621977
9. AF Arnsten 2009 Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction CNS Drugs 23 Suppl 1 33 41 1:CAS:528:DC%2BD1MXhtVGit7%2FL 10.2165/00023210-200923000-00005 19621976
10. AF Sved G Cano JP Card 2001 Neuroanatomical specificity of the circuits controlling sympathetic outflow to different targets Clin Exp Pharmacol Physiol 28 115 119 1:CAS:528:DC%2BD3MXhvVKltg%3D%3D 10.1046/j.1440-1681.2001.03403.x 11153526 (Pubitemid 32039572)
11. J Smythies 2005 Section III. The norepinephrine system Int Rev Neurobiol 64 173 211 10.1016/S0074-7742(05)64003-2 16096022 (Pubitemid 43588577)
12. DB Bylund DC Eikenberg JP Hieble, et al. 1994 International Union of Pharmacology nomenclature of adrenoceptors Pharmacol Rev 46 121 136 1:CAS:528:DyaK2cXlslSlsb4%3D 7938162
13. Newcorn JH, Schulz KP, Halperin JM: Adrenergic agonists: clonidine and guanfacine. In Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS. New York: Oxford University Press; 2003:264-273.
14. C Aoki CG Go C Venkatesan H Kurose 1994 Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity Brain Res 650 181 204 1:CAS:528:DyaK2cXltVSnsLo%3D 10.1016/0006-8993(94)91782-5 7953684 (Pubitemid 24207063)
15. M Scheinin JW Lomasney DM Hayden-Hixson, et al. 1994 Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain Brain Res Mol Brain Res 21 133 149 1:STN:280:DyaK2c3hslClsQ%3D%3D 10.1016/0169-328X(94)90386-7 8164514 (Pubitemid 124014739)
16. T Olli-Lahdesmaki J Kallio M Scheinin 1999 Receptor subtype-induced targeting and subtype-specific internalization of human alpha(2)-adrenoceptors in PC12 cells J Neurosci 19 9281 9288 1:CAS:528:DyaK1MXnslyit74%3D 10531432
17. SL Foote JH Morrison 1987 Extrathalamic modulation of cortical function Annu Rev Neurosci 10 67 95 1:CAS:528:DyaL2sXktVSrtbc%3D 10.1146/annurev.ne.10. 030187.000435 3551766
18. M Wang BP Ramos CD Paspalas, et al. 2007 Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex Cell 129 397 410 1:CAS:528:DC%2BD2sXlsVWlsL4%3D 10.1016/j.cell.2007.03. 015 17448997 (Pubitemid 46574970)
19. BP Ramos D Stark L Verduzco, et al. 2006 Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals Learn Mem 13 770 776 1:CAS:528:DC%2BD2sXhsFahurg%3D 10.1101/lm.298006 17101879 (Pubitemid 44871678)
20. S Uhlen JE Wikberg 1991 Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound Eur J Pharmacol 202 235 243 1:CAS:528:DyaK3MXmslSmsro%3D 10.1016/0014-2999(91)90299-6 1666366
21. P Ernsberger R Giuliano RN Willette DJ Reis 1990 Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla J Pharmacol Exp Ther 253 408 418 1:CAS:528: DyaK3cXktVSntbw%3D 2158551
22. P Ernsberger MP Meeley JJ Mann DJ Reis 1987 Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla Eur J Pharmacol 134 1 13 1:CAS:528:DyaL2sXhtlWlsLY%3D 10.1016/0014-2999(87)90125-7 3030779 (Pubitemid 17015229)
23. PS Goldman-Rakic 1996 The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive Philos Trans R Soc Lond B Biol Sci 351 1445 1453 1:STN:280: DyaK2s%2FpslWrsw%3D%3D 10.1098/rstb.1996.0129 8941956
24. BF Pennington S Ozonoff 1996 Executive functions and developmental psychopathology J Child Psychol Psychiatry 37 51 87 1:STN:280: DyaK283lt1artg%3D%3D 10.1111/j.1469-7610.1996.tb01380.x 8655658 (Pubitemid 26090587)
25. RA Barkley G Grodzinsky GJ DuPaul 1992 Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report J Abnorm Child Psychol 20 163 188 1:STN:280:DyaK383ns1KlsA%3D%3D 10.1007/BF00916547 1593025
26. AF Arnsten BM Li 2005 Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions Biol Psychiatry 57 1377 1384 1:CAS:528:DC%2BD2MXltFSrs74%3D 10.1016/j.biopsych.2004.08.019 15950011 (Pubitemid 40798558)
27. T Sagvolden 2006 The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of attention-deficit/hyperactivity disorder (ADHD) Behav Brain Funct 2 41 10.1186/1744-9081-2-41 17173664 (Pubitemid 46195490)
28. Aston-Jones G, Shipley M, Ennis M, et al.: Restricted afferent control of locus coeruleus neurones revealed by anatomical, physiological, and pharmacological studies. In The Pharmacology of Noradrenaline in the Central Nervous System. Edited by Heal DJ, Marsden CA. New York: Oxford University Press; 1990:187-247.
29. Robbins T, Everitt B: Arousal systems and attention. In The Cognitive Neurosciences. Edited by Gazzaniga MA. Cambridge, MA: MIT Press; 1994:703-720.
30. M Carli TW Robbins JL Evenden BJ Everitt 1983 Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal Behav Brain Res 9 361 380 1:STN:280:DyaL2c%2Flt1ygtA%3D%3D 10.1016/0166-4328(83)90138-9 6639741 (Pubitemid 13002330)
31. J Sirvio M Mazurkiewicz A Haapalinna, et al. 1994 The effects of selective alpha-2 adrenergic agents on the performance of rats in a 5-choice serial reaction time task Brain Res Bull 35 451 455 1:CAS:528:DyaK2MXit1elsro%3D 10.1016/0361-9230(94)90158-9 7859102 (Pubitemid 24342096)
32. G Aston-Jones JD Cohen 2005 An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance Annu Rev Neurosci 28 403 450 1:CAS:528:DC%2BD2MXosVegtbw%3D 10.1146/annurev.neuro.28. 061604.135709 16022602 (Pubitemid 41098911)
33. P Rama I Linnankoski H Tanila, et al. 1996 Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys Pharmacol Biochem Behav 55 415 422 1:CAS:528:DyaK28XntlGhu7g%3D 10.1016/S0091-3057(96)00111-6 8951983 (Pubitemid 26414141)
34. AF Arnsten JX Cai PS Goldman-Rakic 1988 The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes J Neurosci 8 4287 4298 1:CAS:528:DyaL1MXhvVCntA%3D%3D 2903226
35. JS Franowicz AF Arnsten 1998 The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys Psychopharmacology (Berl) 136 8 14 1:CAS:528:DyaK1cXhslemu7Y%3D 10.1007/s002130050533 (Pubitemid 28097515)
36. AF Arnsten TA Contant 1992 Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task Psychopharmacology (Berl) 108 159 169 1:CAS:528:DyaK38Xks1aqsb4%3D 10.1007/BF02245302
37. RA Avery JS Franowicz C Studholme, et al. 2000 The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task Neuropsychopharmacology 23 240 249 1:CAS:528:DC%2BD3cXls1Gisro%3D 10.1016/S0893-133X(00)00111-1 10942848 (Pubitemid 30609658)
38. BM Li ZT Mei 1994 Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys Behav Neural Biol 62 134 139 1:CAS:528: DyaK2cXmvFegur4%3D 10.1016/S0163-1047(05)80034-2 7993303
39. BM Li ZM Mao M Wang ZT Mei 1999 Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys Neuropsychopharmacology 21 601 610 1:CAS:528:DyaK1MXmsFaitrg%3D 10.1016/S0893-133X(99)00070-6 10516956 (Pubitemid 29486628)
40. AF Arnsten JC Steere DJ Jentsch BM Li 1998 Noradrenergic influences on prefrontal cortical cognitive function: opposing actions at postjunctional alpha 1 versus alpha 2-adrenergic receptors Adv Pharmacol 42 764 767 1:CAS:528:DyaK2sXntFaltr8%3D 10.1016/S1054-3589(08)60859-5 9328010
41. H Tanila K Mustonen J Sallinen, et al. 1999 Role of alpha2C-adrenoceptor subtype in spatial working memory as revealed by mice with targeted disruption of the alpha2C-adrenoceptor gene Eur J Neurosci 11 599 603 1:STN:280: DyaK1M7ntF2nuw%3D%3D 10.1046/j.1460-9568.1999.00464.x 10051760 (Pubitemid 29050461)
42. JS Franowicz LE Kessler CM Borja, et al. 2002 Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine J Neurosci 22 8771 8777 1:CAS:528:DC%2BD38Xns1CisLc%3D 12351753
43. JS Franowicz AF Arnsten 2002 Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype Psychopharmacology (Berl) 162 304 312 1:CAS:528:DC%2BD38XntFajsr0%3D 10.1007/s00213-002-1110-6 (Pubitemid 34762290)
44. M Wang ZX Tang BM Li 2004 Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys Brain Res 1024 176 182 1:CAS:528:DC%2BD2cXnvV2lsLY%3D 10.1016/j.brainres.2004.07.062 15451380 (Pubitemid 39286728)
45. JT Coull BJ Sahakian HC Middleton, et al. 1995 Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search Psychopharmacology (Berl) 121 222 230 1:CAS:528:DyaK2MXosF2ktLo%3D 10.1007/BF02245633
46. E Mervaala K Alhainen EL Helkala, et al. 1993 Electrophysiological and neuropsychological effects of a central alpha 2-antagonist atipamezole in healthy volunteers Behav Brain Res 55 85 91 1:CAS:528:DyaK3sXlvFGmt7k%3D 10.1016/0166-4328(93)90010-N 8101086 (Pubitemid 23212767)
47. A Smith D Nutt 1996 Noradrenaline and attention lapses Nature 380 291 1:CAS:528:DyaK28XhvFyrsLs%3D 10.1038/380291a0 8598925
48. P Jakala M Riekkinen J Sirvio, et al. 1999 Guanfacine, but not clonidine, improves planning and working memory performance in humans Neuropsychopharmacology 20 460 470 1:CAS:528:DyaK1MXit1Oht7o%3D 10.1016/S0893-133X(98)00127-4 10192826 (Pubitemid 29123873)
49. P Jakala M Riekkinen J Sirvio, et al. 1999 Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers Neuropsychopharmacology 21 495 502 1:CAS:528:DyaK1MXlslekt78%3D 10.1016/S0893-133X(99)00048-2 10481832 (Pubitemid 29414793)
50. P Jakala J Sirvio M Riekkinen, et al. 1999 Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans Neuropsychopharmacology 20 119 130 1:CAS:528: DyaK1MXjvFKmsA%3D%3D 10.1016/S0893-133X(98)00055-4 9885792 (Pubitemid 29010371)
51. A Lee AE Wissekerke DL Rosin KR Lynch 1998 Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system Neuroscience 84 1085 1096 1:CAS:528: DyaK1cXjtVemt74%3D 10.1016/S0306-4522(97)00578-2 9578397 (Pubitemid 28157025)
52. SM Clerkin KP Schulz JM Halperin, et al. 2009 Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals Biol Psychiatry 66 307 312 1:CAS:528:DC%2BD1MXptlWksrk%3D 10.1016/j.biopsych.2009.04.013 19520360
53. JT Coull AC Nobre CD Frith 2001 The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting Cereb Cortex 11 73 84 1:STN:280: DC%2BD3M7js1OqsA%3D%3D 10.1093/cercor/11.1.73 11113036
54. Y Choi JC Novak A Hillier, et al. 2006 The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility Cogn Behav Neurol 19 204 207 10.1097/01.wnn.0000213919.95266.0d 17159617 (Pubitemid 44973364)
55. U Muller L Clark ML Lam, et al. 2005 Lack of effects of guanfacine on executive and memory functions in healthy male volunteers Psychopharmacology (Berl) 182 205 213 10.1007/s00213-005-0078-4 (Pubitemid 41464613)
56. MM McClure DM Barch MJ Romero, et al. 2007 The effects of guanfacine on context processing abnormalities in schizotypal personality disorder Biol Psychiatry 61 1157 1160 1:CAS:528:DC%2BD2sXkvFOrurg%3D 10.1016/j.biopsych.2006. 06.034 16950221 (Pubitemid 46669454)
57. L Scahill PB Chappell YS Kim, et al. 2001 A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder Am J Psychiatry 158 1067 1074 1:STN:280: DC%2BD3MznsVegtQ%3D%3D 10.1176/appi.ajp.158.7.1067 11431228 (Pubitemid 32623110)
58. BE Swartz CR McDonald A Patel D Torgersen 2008 The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls Clin Neuropharmacol 31 251 260 1:CAS:528:DC%2BD1cXhtF2ku7fK 10.1097/WNF.0b013e3181633461 18836342
59. AM Llorente RG Voigt CL Jensen, et al. 2006 Performance on a visual sustained attention and discrimination task is associated with urinary excretion of norepinephrine metabolite in children with attention-deficit/hyperactivity disorder (AD/HD) Clin Neuropsychol 20 133 144 10.1080/13854040490888495 16393924 (Pubitemid 43062356)
60. CC Overtoom MN Verbaten C Kemner, et al. 2003 Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder Behav Brain Res 145 7 15 1:CAS:528: DC%2BD3sXnslSksr0%3D 10.1016/S0166-4328(03)00097-4 14529800 (Pubitemid 37188627)
61. SR Chamberlain N Del Campo J Dowson, et al. 2007 Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder Biol Psychiatry 62 977 984 1:CAS:528:DC%2BD2sXhtF2htbfL 10.1016/j.biopsych.2007.03. 003 17644072 (Pubitemid 47562368)
62. IR Gizer C Ficks ID Waldman 2009 Candidate gene studies of ADHD: a meta-analytic review Hum Genet 126 51 90 1:CAS:528:DC%2BD1MXoslaksb4%3D 10.1007/s00439-009-0694-x 19506906
63. ID Waldman JT Nigg IR Gizer, et al. 2006 The adrenergic receptor alpha-2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD Cogn Affect Behav Neurosci 6 18 30 10.3758/CABN.6.1.18 16869226
64. MA Bellgrove JB Mattingley Z Hawi, et al. 2006 Impaired temporal resolution of visual attention and dopamine beta hydroxylase genotype in attention-deficit/hyperactivity disorder Biol Psychiatry 60 1039 1045 1:CAS:528:DC%2BD28XhtFKmtLjL 10.1016/j.biopsych.2006.03.062 16876143 (Pubitemid 44647219)
65. C Kieling JP Genro MH Hutz LA Rohde 2008 The -1021 C/T DBH polymorphism is associated with neuropsychological performance among children and adolescents with ADHD Am J Med Genet B Neuropsychiatr Genet 147B 485 490 10.1002/ajmg.b.30636 18081028 (Pubitemid 351830808)
66. G Onesti KD Bock V Heimsoth, et al. 1971 Clonidine: A new antihypertensive agent Am J Cardiol 28 74 83 1:STN:280:DyaE3M3jsFWlug%3D%3D 10.1016/0002-9149(71)90037-3 4933458
67. FC Daniel EF Kenneth MS James 1999 A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder J Am Acad Child Adolesc Psychiatry 38 1551 1559 10.1097/00004583-199912000-00017
68. DJ Posey CJ McDougle 2007 Guanfacine and guanfacine extended release: treatment for ADHD and related disorders CNS Drug Rev 13 465 474 1:CAS:528:DC%2BD1cXhtVOrsLo%3D 10.1111/j.1527-3458.2007.00026.x 18078429 (Pubitemid 350233473)
69. FB Taylor J Russo 2001 Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder J Clin Psychopharmacol 21 223 228 1:CAS:528:DC%2BD3MXisV2qsb0%3D 10.1097/00004714- 200104000-00015 11270920 (Pubitemid 32221061)
70. JC Kisicki K Fiske A Lyne 2007 Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years Clin Ther 29 1967 1979 1:CAS:528:DC%2BD2sXhtlakt7vE 10.1016/j.clinthera.2007.09.020 18035196 (Pubitemid 350212810)
71. SW Boellner M Pennick K Fiske, et al. 2007 Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder Pharmacotherapy 27 1253 1262 1:CAS:528:DC%2BD2sXhtVOku7%2FJ 10.1592/phco.27.9.1253 17723079 (Pubitemid 47339123)
72. D Swearingen M Pennick A Shojaei, et al. 2007 A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults Clin Ther 29 617 625 1:CAS:528:DC%2BD2sXmvVWnu74%3D 10.1016/j.clinthera.2007.04.016 17617285
73. FR Sallee J McGough T Wigal, et al. 2009 Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry 48 155 165 10.1097/CHI.0b013e318191769e 19106767
74. Kollins SH, Spencer TJ, Findling RL, et al.: Effects of guanfacine extended release in children aged 6 to 12 with oppositional symptoms and a diagnosis of ADHD. Presented at the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI; October 27-November 1, 2009.
75. FR Sallee A Lyne T Wigal JJ McGough 2009 Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder J Child Adolesc Psychopharmacol 19 215 226 10.1089/cap.2008.0080 19519256
76. J Biederman RD Melmed A Patel, et al. 2008 Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD CNS Spectr 13 1047 1055 1:STN:280:DC%2BD1M7gsF2jtQ%3D%3D 19179940
77. Jain R, Kollins SH, Baily C, et al.: Developing a sustained release formulation of clonidine for the treatment of children and adolescents with attention-deficit hyperactivity disorder (ADHD). Presented at the 47th Annual Meeting of the American College of Neuropsychopharmacology. Scottsdale, AZ; December 7-11, 2008.
78. Kollins SH, Findling RL, Wigal SB, et al.: Modified-release clonidine for the treatment of children/adolescents with ADHD. Presented at the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI; October 27-November 1, 2009.
79. T Sagvolden EB Johansen H Aase VA Russell 2005 A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes Behav Brain Sci 28 397 419 10.1017/S0140525X05000075 16209748 discussion 419-468 (Pubitemid 41440193)